Zilver® PTX® V Clinical Study

NCT ID: NCT01901289

Last Updated: 2022-03-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2021-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Zilver® PTX® V Clinical Study is a post-market clinical trial required by the US FDA to provide continued evaluation of the safety and effectiveness of the Zilver PTX Drug-Eluting Peripheral Stent in treatment of narrowing of the femoropopliteal arteries.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Drug-Eluting Stent

Group Type EXPERIMENTAL

Zilver® PTX® Drug-Eluting Peripheral Stent

Intervention Type DEVICE

Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zilver® PTX® Drug-Eluting Peripheral Stent

Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient has signed and dated the informed consent.
* Patient has symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
* Patient agrees to return for the required follow-up assessments.

Exclusion Criteria

* Patient is \< 18 years of age.
* Patient has significant stenosis of inflow tract not successfully treated before this procedure.
* Patient lacks at least one patent vessel of runoff with \< 50% stenosis throughout its course.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cook Research Incorporated

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

VA Palo Alto Health Care System

Palo Alto, California, United States

Site Status

Stanford University Medical School

Stanford, California, United States

Site Status

Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

The Cardiac and Vascular Institute

Gainesville, Florida, United States

Site Status

University of Florida

Gainesville, Florida, United States

Site Status

First Coast Cardiovascular Institute

Jacksonville, Florida, United States

Site Status

Alexian Brothers Medical Center

Elk Grove Village, Illinois, United States

Site Status

Bayview Medical Center

Baltimore, Maryland, United States

Site Status

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

New York-Presbyterian/ Weill Cornell Medical Center

New York, New York, United States

Site Status

OhioHealth Research Institute

Columbus, Ohio, United States

Site Status

University of Toledo Medical Center

Toledo, Ohio, United States

Site Status

Holy Spirit Hospital

Camp Hill, Pennsylvania, United States

Site Status

South Carolina Heart Center

Columbia, South Carolina, United States

Site Status

Greenville Hospital System

Greenville, South Carolina, United States

Site Status

Holston Valley Hospital

Kingsport, Tennessee, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Dake MD, Fanelli F, Lottes AE, O'Leary EE, Reichert H, Jiang X, Fu W, Iida O, Zen K, Schermerhorn M, Zeller T, Ansel GM. Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent. Cardiovasc Intervent Radiol. 2021 Feb;44(2):196-206. doi: 10.1007/s00270-020-02648-6. Epub 2020 Oct 6.

Reference Type DERIVED
PMID: 33025243 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

12-004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Zenith® Dissection Clinical Trial
NCT01568320 COMPLETED NA